Jefferies Maintains a 'Buy/Top Pick' on Valeant Pharmaceuticals (VRX); Taking the Right Medic(is)ine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Barclays Maintains an 'Equalweight' on Medicis (MRX); Is Another Bidder Out There?
September 5, 2012 1:39 PM EDTBarclays maintains an 'Equalweight' on Medicis (NYSE: MRX) price target of $44.00 (from $35.00).
Analyst, Douglas D. Tsao, said, "With MRX trading ~1.5% below deal price, implying an annualized retun >3%, tighter than typical merger spreads, MRX shares appear to reflect some likelihood of another bidder... More
UBS Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Deal Supports Thesis; Stock Move Justified
September 5, 2012 10:16 AM EDTUBS maintains a 'Buy' on Valeant Pharmaceuticals (NYSE: VRX) price target of $70.00 (from $64.00).
Analyst, Marc Goo dman, said, "How were thinking about the deal Model updates We assume (1) modest changes for a few prods (lower Zyclara and Renova sales), (2) divestiture of Carac (Zyclara overlap)... More
Goldman Sachs Downgrades Medicis (MRX) to Neutral; Limited Upside From Deal Now
September 5, 2012 8:37 AM EDTGoldman Sachs downgraded Medicis (NYSE: MRX) from Buy to Neutral with a price target of $44.00 (from $42.00).
Analyst, Gregory Waterman, said, "We now see limited upside to our updated price target of $44. MRX shares rallied 38% following the announcement that the company had... More
